Health
Chronicle Pharmabiz
US FDA fortifies alliance with Telangana DCA
A high-level delegation from the US FDA concluded a significant meeting with the DCA in Telangana, two days ago, at the DCA office in Hyderabad.
2 min |
December 11, 2025
Chronicle Pharmabiz
India exploring possibilities to expand WHO standards for Indian medicines
INDIA is looking at possibilities to expand the World Health Organisation (WHO) global benchmarking standards for medicines, in order to unify and strengthen the drug regulatory mechanism for safety, quality and efficacy of medicines sold in the country.
1 min |
December 11, 2025
Chronicle Pharmabiz
Eli Lilly gets US FDA approval for Jaypirca
Eli Lilly and Company announced that the US Food and Drug Administration (FDA) has granted approval to Jaypirca (pirtobrutinib, 100 mg & 50 mg tablets) for the treatment of adults with relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma (CLL/SLL) who have previously been treated with a covalent Bruton tyrosine kinase (BTK) inhibitor.
1 min |
December 11, 2025
Chronicle Pharmabiz
Haryana DCA focuses on quality overhaul
THE Haryana drug control administration (DCA) is undertaking a major organizational overhaul focused on quality system upgrades and regulatory capacity building, particularly in response to the revised Schedule M norms.
2 min |
December 11, 2025
Chronicle Pharmabiz
DoC seeks inputs on trade issues faced with Japan
THE Department of Commerce (DoC), under the Union Commerce Ministry, has sought inputs from the industry on specific issues being faced in pharma trade with Japan.
1 min |
December 11, 2025
Chronicle Pharmabiz
AIOCD asks traders to strictly comply with ban on 35 FDCs
THE All India Organisation of Chemists and Druggists (AIOCD) has issued an urgent internal circular to all its state and Union territory trade bodies, demanding immediate and strict compliance with the ban on 35 fixed dose combinations (FDCs).
3 min |
December 11, 2025
Chronicle Pharmabiz
US FDA approves Bristol Myers Squibb's Breyanzi
Bristol Myers Squibb announced that the US Food and Drug Administration (FDA) has granted approval of Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for the treatment of adult patients with relapsed or refractory (R/R) marginal zone lymphoma (MZL) who have received at least two prior lines of systemic therapy.
2 min |
December 11, 2025
Chronicle Pharmabiz
CN Water presents AQU@Sense MB
CN Water is now combining core water-system expertise with digital assurance has launched AQU@Sense which delivers microbial test results in under 30 minutes, replacing traditional 5 to 7 days culture based methods.
1 min |
December 11, 2025
Chronicle Pharmabiz
Pharma logistics sees policy push as key catalyst for growth
INDIAN pharma's logistics sector is getting major boost from emerging policy support.
2 min |
December 11, 2025
Chronicle Pharmabiz
Lack of financial aid, expertise mar MSME prospects to meet revised Sch M deadline
INDUSTRY experts have raised alarm that lack of financial assistance and guidance on technical expertise have marred pharma MSMEs’ prospects to comply with revised Schedule M guidelines of December 31, 2025.
2 min |
December 11, 2025
Chronicle Pharmabiz
Import of bulk drugs, intermediates declines over 11% in October
IMPORTS of bulk drugs and intermediates to India registered a decline of 11.14% in the month of October, 2025, while the quantity of imports grew 20.74% during the month as compared to the same period of previous year.
2 min |
December 11, 2025
Chronicle Pharmabiz
Indian pharma ramps up global alignment
INDIAN pharma is accelerating its push toward global regulatory harmonization as authorities intensify efforts to align domestic standards with stringent International Council for Harmonisation (ICH) and World Health Organization (WHO) norms.
1 min |
December 11, 2025
Chronicle Pharmabiz
CDSCO announces risk classification of 119 medical devices
THE Central Drugs Standard Control Organisation (CDSCO) has announced risk classification of 119 medical devices pertaining to radiotherapy under the Medical Devices Rules (MDR), 2017, as part of updating classification of devices in order to keep regulating various medical devices under the rules.
2 min |
December 11, 2025
Chronicle Pharmabiz
Afghanistan initiates talks with Pharmexcil
A recent Afghan ministerial delegation to India has resulted in the initiation of focussed discussions with the Pharmaceuticals Export Promotion Council of India (Pharmexcil) towards strengthening bilateral cooperation in the pharma sector.
1 min |
December 11, 2025
Chronicle Pharmabiz
Growing Graph of IP
BOTSWANA has become the 18th country to recognize Indian Pharmacopoeia (IP) as a book of standard for medicines when it signed an MoU with the Indian government during Indian President Droupadi Murmu's recent visit to Botswana.
2 min |
December 11, 2025
Chronicle Pharmabiz
Innovent closes global collaboration with Takeda
INNOVENT Biologics, a leading biopharmaceutical company, announced that the global strategic collaboration with Takeda has closed and become effective following the satisfaction of all closing conditions.
1 min |
December 11, 2025
Chronicle Pharmabiz
AIOCD enforces mandatory 'MRP Minus 25%' rule for LBE claims
THE All India Organisation of Chemists and Druggists (AIOCD) has issued anew, internal mandatory circular demanding immediate and strict compliance from pharmaceutical stockists and companies regarding the settlement of loss before expiry (LBE) claims.
2 min |
December 11, 2025
Chronicle Pharmabiz
Ayurveda market booms in India even as US tariffs deliver a blow
INDIA'S Ayurveda sector is experiencing strong domestic momentum, driven by rising consumer preference for natural wellness products, expanded retail presence, and greater government support for Ayush initiatives.
2 min |
December 11, 2025
Chronicle Pharmabiz
IPC to come out with IP 2026 to strengthen standards of drugs
IN order to further strengthen the standards of drugs in India, the Indian Pharmacopoeia Commission (IPC) is coming out with the publication of 10th edition of the Indian Pharmacopoeia (IP 2026).
1 min |
December 11, 2025
Chronicle Pharmabiz
Interdisciplinary approach for Atypical Parkinsonism
A TYPICAL Parkinsonism, a collection of neurodegenerative diseases that share symptoms with Parkinson's Disease but have unique features, poses challenges for patients and healthcare providers.
5 min |
December 11, 2025
Chronicle Pharmabiz
Govt proposes rules for renewal of regn for surrogacy clinics
THE Union health ministry has issued a draft amendment to the Surrogacy (Regulation) Rules, 2022, elaborating the manner of renewal of registration of surrogacy clinics, proposing a fee of Rs. 1 lakh for renewal and that the validity of renewal will be for a period of three years from the date of expiry of the prevailing registration.
1 min |
December 11, 2025
Chronicle Pharmabiz
NCISM allows 31 new Ayurveda Medical Colleges in AY 2025-26
THE National Commission for Indian System of Medicine (NCISM) has granted Letter of Intent (LOI) or Letter of Permission (LOP) to a total of 31 entities till November 19, 2025 to establish new Ayurveda Medical Colleges during the academic year 2025-26 to conduct undergraduate courses adding a total of over 2,600 seats to the existing Under Graduate (UG) Bachelor of Ayurvedic Medicine and Surgery (BAMS) seats.
1 min |
December 11, 2025
Chronicle Pharmabiz
Pharma braces for mixed Impact as rupee breaches ₹90 mark
As the Indian rupee breaching Rs. 90 mark against US dollar has sparked concerns across import heavy industries, the pharmaceutical sector which is one of the country's most export-driven sectors expects a nuanced and mixed outcome, according to industry experts.
1 min |
December 11, 2025
Chronicle Pharmabiz
Odisha Pharma Summit 2025 to be held on Dec 16, 2025
THE much-anticipated Odisha Pharma Summit 2025, a high-stakes event aimed at positioning the state as the pharmaceutical powerhouse of Eastern India, has been officially rescheduled.
2 min |
December 11, 2025
Chronicle Pharmabiz
India must fast-track talent training pipelines in CGT: Expert
INDIA's efforts to become a global hub for cell and gene therapy (CGT) manufacturing are being constrained by a widening skills gap across advanced bioprocessing, analytics, and clinical-grade production.
2 min |
December 11, 2025
Chronicle Pharmabiz
DCC opines consultation on use of same brand name for multiple formulations
THE Drugs Consultative Committee advisory (DCC), the committee that advises the Central and state governments on matters that require uniform implementation of drug laws across the country, has opined that a stakeholder consultation should be carried out by considering various matters in connection with addressing the issues related to use of same brand name with extensions for multiple drug formulations.
2 min |
December 11, 2025
Chronicle Pharmabiz
BDCDA asks cos to strengthen ethical pharma distribution
THE Bangalore District Chemists and Druggists Association (BDCDA) has asked the pharma manufacturers, marketers and C&F Agents to strengthen the ethical pharmaceutical distribution in Karnataka by making the intrastate systemic corrections in credit structures.
2 min |
December 11, 2025
Chronicle Pharmabiz
FIP unveils Plan for 2025-30 to guide global pharmacy
INTERNATIONAL Pharmaceutical Federation (FIP) has launched a bold new Strategic Plan 2025-2030 to guide the global pharmacy profession into the future.
1 min |
December 11, 2025
Chronicle Pharmabiz
IPC to revive focus on strengthening PV, MV in NE region
THE Indian Pharmacopoeia Commission (IPC) is chalking out a roadmap with revival of focus towards strengthening pharmacovigilance (PV) and materiovigilance (MV) in the North Eastern (NE) region towards reporting medicine related adverse drug reactions (ADRs) and medical devices related adverse events (MDAEs).
1 min |
December 11, 2025
Chronicle Pharmabiz
CBC India unveils Ingredients & Pkg Solutions
India unveils its next big step the launch of its excipient business under its new identity, 'Ingredients & Packaging Solutions'.
1 min |